Skip to main content

Table 3 Ongoing phase 3 clinical trials for intermediate or early stage hepatocellular carcinoma

From: Emerging agents and regimens for hepatocellular carcinoma

Trial Settings Arms Clinicaltrials.gov identifier Sponsor
EMERALD-1 intermediate stage, first line TACE + durvalumab ± bevacizumab vs TACE + placebo NCT03778957 AstraZeneca
CheckMate 9DX Early stage, adjuvant therapy Nivolumab vs placebo NCT03383458 BMS
EMERALD-2 Early stage, adjuvant therapy Durvalumab + bevacizumab vs durvalumab + placebo vs placebo NCT03847428 AstraZeneca
KEYNOTE-937 Early stage, adjuvant therapy Pembrolizumab vs placebo NCT03867084 MSD
JUPITER 04 Early stage, adjuvant therapy Toripalimab vs placebo NCT03859128 Junshi
  1. TACE transcatheter chemoembolization